Aveo Pharmaceuticals (AVEO) 0.65 $AVEO
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 22.15 (-0.91), KOS: 7.29 (-0.07), KIN: 6.67 (-0.01), VSAT: 62.66 (-0.88), RFMD: 15.50 (-0.29), EBAY: 55.77 (-1.01), TQNT: 25.87 (-0.51), IDIX: 24.50 (+0.05), SEMI: 18.42 (+0.35), VRTV: 47.95 (-0.05), THRX: 13.39 (-0.37), TBPH: 13.91 (-0.10), IMOS: 23.26 (+0.14), ELOS: 10.01 (-0.10), MU: 34.00 (-1.19), AR: 39.89 (+0.67), NCQ: 0.57 (+0.01), PBF: 27.36 (-0.22), LNG: 64.88 (+0.93), ATRA: 25.49 (-2.11), KERX: 14.50 (-0.62), NG: 2.68 (+0.02), AOI: 1.56 (-0.05), FWP: 19.97 (+0.06), BYD: 11.27 (-0.25), ALDW: 12.50 (-0.57), SUNE: 18.55 (-0.47), MRK: 57.72 (-1.62), AVEO: 0.65 (-0.03), AIG: 54.05 (-1.13)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 48.83 (+1.19), AVEO: 0.65 (-0.03), AMAG: 40.04 (-0.79)
Aveo licenses tivozanib to Ophthotech
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:55AM CST
OPHT: 48.83 (+1.19), AVEO: 0.65 (-0.03)
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.65 (-0.03), OPHT: 48.83 (+1.19)
AVEO Pharmaceuticals misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:55PM CST
AVEO: 0.65 (-0.03)
Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:10PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report third-quarter 2014 results on Nov 6, had delivered a positive earnings surprise of 7.89% last quarter.
BIIB: 344.49 (+2.16), AVEO: 0.65 (-0.03), INFI: 17.78 (-0.21), HSP: 60.33 (-1.75)
AVEO Oncology Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:17PM CST
AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
AVEO: 0.65 (-0.03)
Global Cancer Kinase Inhibitors Market & Pipeline Insight 2014: 649 Pipeline Drugs & 35 Marketed Drugs
M2 - Mon Oct 13, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btwzfw/global_cancer) has announced the addition of the "Global Cancer Kinase Inhibitors Market & Pipeline Insight" report to their offering. The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs. The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs. Additionally, with the industry undergoing the period of patent cliff, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients. Global Cancer Kinase Inhibitors Market & Pipeline Insight Report Highlights: - Classification & Mechanism of Kinase Inhibitors - Cancer Kinase Inhibitors Therapy Market Overview - Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country - Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country - Patent Analysis & Orphan Designation of Kinase Inhibitors - Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs - Marketed Cancer Kinase Inhibitors: 35 Drugs Key Topics Covered: 1. Introduction to Kinase Inhibitors 2. Kinase Inhibitors Classification 3. Mechanisms of Kinase Inhibitors 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 11. Competitive Landscape - AVEO Pharmaceuticals - Amgen - AstraZeneca - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Deciphera Pharmaceuticals - Genentech - GlaxoSmithKline - Incyte Corporation - Novartis - Pfizer - Takeda For more information visit http://www.researchandmarkets.com/research/bt...bal_cancer
INCY: 74.65 (-1.27), AVEO: 0.65 (-0.03), AMGN: 164.53 (-1.55), GSK: 42.42 (-0.93), NVS: 93.52 (-0.82)
HILL, AVEO, ORBC Expected To Be Down Before Next Earnings Releases
M2 - Tue Oct 07, 5:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Dot Hill Systems Corp (NASDAQ:HILL), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), ORBCOMM Inc (NASDAQ:ORBC) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
HILL: 4.26 (-0.08), AVEO: 0.65 (-0.03), ORBC: 6.52 (+0.01)
AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 2:30PM CDT
AVEO Pharmaceuticals, Inc. (AVEO) and Biodesix announced data from an exploratory analysis of patients suffering from non small cell lung cancer (NSCLC) in a phase II study on ficlatuzumab.
MDVN: 106.86 (-1.16), GILD: 104.13 (-0.18), AZN: 71.80 (-1.80), AVEO: 0.65 (-0.03)
BioMed Leases Space to Baxter for R&D Center in MA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 9:40AM CDT
BioMed Realty Trust, Inc. (BMR) inked a new deal with Baxter Healthcare Corporation for leasing around 200,000 square feet of space in Cambridge, MA.
BMR: 21.33 (-0.25), PRU: 86.66 (-3.13), BAX: 71.77 (-1.34), AVEO: 0.65 (-0.03)
AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress
Business Wire - Mon Sep 29, 5:45AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25-30 in Madrid, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) with a long half-life and activity against all three VEGF receptors.
AVEO: 0.65 (-0.03)
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress
Business Wire - Mon Sep 29, 5:00AM CDT
AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat(R), a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO's HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA(R)) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
AVEO: 0.65 (-0.03)
AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
Business Wire - Fri Sep 26, 10:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, the AVEO research was selected for presentation in an oral session titled "Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia."
AVEO: 0.65 (-0.03)
AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility
Business Wire - Fri Sep 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company's headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million. In addition, the Company has amended its debt financing facility with Hercules Technology Growth Capital (HTGC). Combined, these transactions do not impact the Company's prior financial guidance, with existing cash, cash equivalents and marketable securities providing resources to fund its operating plan into the fourth quarter of 2015 with an expected 2014 year-end cash balance of $50-55 million.
HTGC: 14.44 (-0.42), AVEO: 0.65 (-0.03)
Clinical Data on AVEO Oncology's Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress
Business Wire - Wed Sep 17, 5:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company's hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company's inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 - September 30, 2014.
AVEO: 0.65 (-0.03)
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:00AM CDT
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue?
AVEO: 0.65 (-0.03)
Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.
ACHN: 13.28 (-0.11), AVEO: 0.65 (-0.03), AEGR: 21.09 (-0.22), RTGN: 3.83 (-0.17)
AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:30AM CDT
AVEO Pharmaceuticals reported a second-quarter 2014 loss of 35 cents per share.
ENDP: 68.77 (-2.45), AVEO: 0.65 (-0.03), ANAC: 33.86 (-0.82)
AVEO Oncology Reports Second Quarter 2014 Financial Results and Updates Progress on Strategic Plan
Business Wire - Mon Aug 11, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
AVEO: 0.65 (-0.03)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 22.15 (-0.91), KOS: 7.29 (-0.07), KIN: 6.67 (-0.01), VSAT: 62.66 (-0.88), RFMD: 15.50 (-0.29), EBAY: 55.77 (-1.01), TQNT: 25.87 (-0.51), IDIX: 24.50 (+0.05), SEMI: 18.42 (+0.35), VRTV: 47.95 (-0.05), THRX: 13.39 (-0.37), TBPH: 13.91 (-0.10), IMOS: 23.26 (+0.14), ELOS: 10.01 (-0.10), MU: 34.00 (-1.19), AR: 39.89 (+0.67), NCQ: 0.57 (+0.01), PBF: 27.36 (-0.22), LNG: 64.88 (+0.93), ATRA: 25.49 (-2.11), KERX: 14.50 (-0.62), NG: 2.68 (+0.02), AOI: 1.56 (-0.05), FWP: 19.97 (+0.06), BYD: 11.27 (-0.25), ALDW: 12.50 (-0.57), SUNE: 18.55 (-0.47), MRK: 57.72 (-1.62), AVEO: 0.65 (-0.03), AIG: 54.05 (-1.13)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 48.83 (+1.19), AVEO: 0.65 (-0.03), AMAG: 40.04 (-0.79)
Aveo licenses tivozanib to Ophthotech
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:55AM CST
OPHT: 48.83 (+1.19), AVEO: 0.65 (-0.03)
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.65 (-0.03), OPHT: 48.83 (+1.19)
AVEO Pharmaceuticals misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:55PM CST
AVEO: 0.65 (-0.03)
Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:10PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report third-quarter 2014 results on Nov 6, had delivered a positive earnings surprise of 7.89% last quarter.
BIIB: 344.49 (+2.16), AVEO: 0.65 (-0.03), INFI: 17.78 (-0.21), HSP: 60.33 (-1.75)
AVEO Oncology Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:17PM CST
AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
AVEO: 0.65 (-0.03)
Global Cancer Kinase Inhibitors Market & Pipeline Insight 2014: 649 Pipeline Drugs & 35 Marketed Drugs
M2 - Mon Oct 13, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btwzfw/global_cancer) has announced the addition of the "Global Cancer Kinase Inhibitors Market & Pipeline Insight" report to their offering. The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs. The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs. Additionally, with the industry undergoing the period of patent cliff, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients. Global Cancer Kinase Inhibitors Market & Pipeline Insight Report Highlights: - Classification & Mechanism of Kinase Inhibitors - Cancer Kinase Inhibitors Therapy Market Overview - Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country - Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country - Patent Analysis & Orphan Designation of Kinase Inhibitors - Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs - Marketed Cancer Kinase Inhibitors: 35 Drugs Key Topics Covered: 1. Introduction to Kinase Inhibitors 2. Kinase Inhibitors Classification 3. Mechanisms of Kinase Inhibitors 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 11. Competitive Landscape - AVEO Pharmaceuticals - Amgen - AstraZeneca - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Deciphera Pharmaceuticals - Genentech - GlaxoSmithKline - Incyte Corporation - Novartis - Pfizer - Takeda For more information visit http://www.researchandmarkets.com/research/bt...bal_cancer
INCY: 74.65 (-1.27), AVEO: 0.65 (-0.03), AMGN: 164.53 (-1.55), GSK: 42.42 (-0.93), NVS: 93.52 (-0.82)
HILL, AVEO, ORBC Expected To Be Down Before Next Earnings Releases
M2 - Tue Oct 07, 5:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Dot Hill Systems Corp (NASDAQ:HILL), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), ORBCOMM Inc (NASDAQ:ORBC) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
HILL: 4.26 (-0.08), AVEO: 0.65 (-0.03), ORBC: 6.52 (+0.01)
AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 2:30PM CDT
AVEO Pharmaceuticals, Inc. (AVEO) and Biodesix announced data from an exploratory analysis of patients suffering from non small cell lung cancer (NSCLC) in a phase II study on ficlatuzumab.
MDVN: 106.86 (-1.16), GILD: 104.13 (-0.18), AZN: 71.80 (-1.80), AVEO: 0.65 (-0.03)
BioMed Leases Space to Baxter for R&D Center in MA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 9:40AM CDT
BioMed Realty Trust, Inc. (BMR) inked a new deal with Baxter Healthcare Corporation for leasing around 200,000 square feet of space in Cambridge, MA.
BMR: 21.33 (-0.25), PRU: 86.66 (-3.13), BAX: 71.77 (-1.34), AVEO: 0.65 (-0.03)
AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress
Business Wire - Mon Sep 29, 5:45AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25-30 in Madrid, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) with a long half-life and activity against all three VEGF receptors.
AVEO: 0.65 (-0.03)
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress
Business Wire - Mon Sep 29, 5:00AM CDT
AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat(R), a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO's HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA(R)) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
AVEO: 0.65 (-0.03)
AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
Business Wire - Fri Sep 26, 10:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, the AVEO research was selected for presentation in an oral session titled "Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia."
AVEO: 0.65 (-0.03)
AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility
Business Wire - Fri Sep 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company's headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million. In addition, the Company has amended its debt financing facility with Hercules Technology Growth Capital (HTGC). Combined, these transactions do not impact the Company's prior financial guidance, with existing cash, cash equivalents and marketable securities providing resources to fund its operating plan into the fourth quarter of 2015 with an expected 2014 year-end cash balance of $50-55 million.
HTGC: 14.44 (-0.42), AVEO: 0.65 (-0.03)
Clinical Data on AVEO Oncology's Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress
Business Wire - Wed Sep 17, 5:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company's hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company's inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 - September 30, 2014.
AVEO: 0.65 (-0.03)
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:00AM CDT
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue?
AVEO: 0.65 (-0.03)
Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.
ACHN: 13.28 (-0.11), AVEO: 0.65 (-0.03), AEGR: 21.09 (-0.22), RTGN: 3.83 (-0.17)
AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 8:30AM CDT
AVEO Pharmaceuticals reported a second-quarter 2014 loss of 35 cents per share.
ENDP: 68.77 (-2.45), AVEO: 0.65 (-0.03), ANAC: 33.86 (-0.82)
AVEO Oncology Reports Second Quarter 2014 Financial Results and Updates Progress on Strategic Plan
Business Wire - Mon Aug 11, 3:15PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
AVEO: 0.65 (-0.03)
